Bulletin of Environment, Pharmacology and Life Sciences
Bull. Env. Pharmacol. Life Sci., Vol 12 [7] June 2024: 39-48

Online ISSN 2277-1808
Journal's URL: http://www.bepls.com
CODEN: BEPLAD

REVIEW ARTICLE **OPEN ACCESS**

Protein Engineering: A Holistic Approach to Techniques and Its Uses

Manisha Sharma*, Saumya Goyal, Shaffi Tangri
School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India.
Corresponding Author: Email- manisha.october@gmail.com*

ABSTRACT
With roots in recombinant DNA technology, the field of protein engineering regards gene modifications as changes to protein sequences that bestow desired properties. Protein engineering is considered the next big thing, after genetic engineering. Many methods of precisely constructing proteins may be broadly categorized as methods requiring substantial previous protein interaction, hence introducing the concept of a methodical directed evolution approach that promotes the expression of the natural evolutionary process. One may employ rational design, non-rational design, or both. There are several applications for the emerging field of protein engineering in research, industry, pharmaceutics, trade, and laundry. Protein engineering has made it feasible to create novel proteins with the goal of diagnosing, treating, and improving health. Proteases and amylases are two instances of altered enzyme classes with significant uses in the food, soap, paper, and other industries. Protein engineering can create intricate, stimulus-responsive pharmacological systems that alter the metabolic drug landscapes. Even though protein engineering treatments is still a relatively new field, current developments are being used to directly influence pharmacodynamics. An overview of existing approaches and tactics for altering proteins at various levels is provided in this article, along with information on possible applications in nanobiotechnology, the food sector, and medicine.
Keywords: *protein engineering, nanobiotechnology, recombinant DNA technology, industrial applications, therapeutic enzymes, therapeutic applications*

Received 19.03.2024 Revised 19.04.2024 Accepted 30.05.2024

INTRODUCTION

Studies employing recombinant DNA technology and protein level alterations have reportedly left a mark that has contributed to the emergence of a distinct field known as protein engineering. In order to produce a diversified protein with higher activity and desired qualities, this field of study looks into changing the arrangement of amino acids and their potential impacts. [1] Put more succinctly, protein engineering is defined as "the creation and building of novel proteins, typically by modification of their genes" [2], according to early researchers in the subject. Understanding protein structure is necessary before talking about protein function because, like other macromolecules, structure dictates function. The basic, secondary, tertiary, and quaternary stages of protein folding are the four phases that matter in protein engineering. Simply said, the fundamental structure is the arrangement of amino acids in their unfolded state, locked together by covalent bonds. The arrangement of proteins is dictated by the twenty essential amino acids. "Secondary structure" describes the hydrogen bond-produced local organization of the protein backbone. Alpha helices, which are spirals of amino acids, and beta pleated sheets, which are composed of many parallel or anti-parallel chains, are the two forms of amino acid chains that define this configuration. The tertiary structure of amino acid folds, which includes ionic interactions, hydrogen bonds, Van der Waals forces, hydrophobic interactions, and salt bridges, gives proteins their three-dimensional structure. When the protein reaches its lowest energy state or most stable state, the tertiary structure forms. Two proteins assemble into a quaternary structure during their tertiary phase. Understanding the tertiary structure is crucial for understanding how proteins fold and the logic underlying their correlation in the quaternary phase, making it the most important structure in protein engineering. The protein folds through these four stages in a matter of milliseconds after it is generated.[3] Our knowledge of proteins is now limited to secondary and super secondary structures, and protein folding is a complex process associated with molecular chaperones. Even though computational methods may already generate low-energy 3-D structures [2], a complete comprehension of the protein folding process is still necessary to modify protein structures for applications in biotechnology and functional research. [4] When protein

engineering first gained popularity, its proponents concentrated on employing site-directed mutagenesis to change an enzyme's active site, which swiftly produced a number of biological and biotechnological advancements. Ten years after the first protein variants were generated in 1982, amazing prospects had already arisen for understanding the structure and function of proteins and developing new therapies. Simultaneously, challenges with function design were also noted, and they were linked to the insufficiency of present computational techniques to anticipate sequence and activity from structure [2]. Considerable advancement has been made since then. Protein engineering methods are now widely accessible and used in both fundamental and applied biotechnology research. In sectors where native or organic proteins would not work well, such industry, agriculture, environmental sciences, or other fields, desired-property proteins might be useful. Although they are employed in industry, modified proteins are also utilized in medical and therapeutic settings. In the area of nanobiotechnology, protein engineering might be helpful [5, 6, 7]. An overview of protein engineering techniques and applications throughout history is given on this page.

PROTEIN ENGINEERING TECHNIQUES

Directed evolution of protein catalysts:

In directed evolution, several mutant copies of a gene are produced via targeted or random mutagenesis or computational methods, and these altered copies are then employed to build related proteins. As a result, a library of various proteins is produced, and those with the appropriate qualities are carefully tested and selected. This approach is similar to evolution, where natural selection has developed a wide range of large protein families throughout time. While this method is laborious and time-consuming, by focusing on a limited number of protein alterations, researchers in related fields have developed a similar strategy that can be completed in a few weeks in the lab. This is due to the fact that every codon modification raises the coverage complexity. [8, 9, 10]

Rational protein designing:

The less common protein engineering method is rational design. To produce a protein that carries out the intended function, rational design entails either starting from scratch or directly altering an already-existing protein. In the previous example, if someone wanted to design a protein that might be able to break down fructose, they could begin by running a simulation program that used a model of the enzyme sucraseisomaltase. If the simulation showed that the enzyme was able to bind and break down fructose, they could then modify the enzyme immediately. After obtaining the required protein model, the scientist would use a process called oligonucleotide synthesis with annealing to build an in vitro gene that codes for the protein. This gene would be inserted into an E. coli cell, the researcher would watch for the host to produce the protein, and then they would remove it. It is crucial that the model that the investigator began with be extremely accurate during this process since even little differences between the genuine protein as well as the simulated model can have a significant impact on the manner in which a protein folds after producing mutations. [11] The rational design method frequently requires several iterations, but throughout each iteration, new insights into the protein's structure and functionality are discovered.

Overlap Extension Method:

The overlap extension method makes use of two pairs of primers. A codon mutation has resulted in a discordant sequence in one primer of these two primer pairs. Following the first cycle of the polymerase chain reaction (PCR) using these two primer pairs, each pair is employed in two distinct processes [9]. Two double-stranded DNAs are produced by these two reactions (dsDNA). Two heteroduplex DNAs are created when these two dsDNAs are denaturated and annealed. Every strand of heteroduplex DNA will include the altered codon since one primer from every single primer pair has a mismatched sequence. DNA polymerase fills in the overlapping regions of the heteroduplex DNA strands. Then, using a typical primer pair, the mutagenic heteroduplex DNA is amplified in a second PCR to produce numerous copies [12, 13, 14].

Whole plasmid single round polymerase chain reaction technique:

Two oligonucleotide primers that correspond to the dsDNA of the plasmid that acts as a particular template are utilized in entire plasmid single round PCR. [15] The intended mutation is included in the sequence of these primers by design. DNA polymerase duplicates the plasmid's two strands during PCR. Since the primers complement dsDNA, they do not cause the plasmid to mutate since they are not removed from it. The plasmid that has undergone mutation does have breaks, but they do not cross across. DpnI, a restriction enzyme, is utilised to digest the altered plasmid alone [16]. DpnI generates a circular plasmid vector with nicks in it. DNA polymerase repairs the DNA nick in the transformed competent cells utilizing this nicked plasmid vector, resulting in the creation of a circular mutant plasmid. The intended gene product is then produced by the host through the expression of the modified plasmid. [13, 17].

Random mutagenesis:

Protein diversification can occur in vivo or in vitro, either randomly or deliberately. Alternatively, a range of proteins are now available for analysis, and gene modifications that may be advantageous are being

found using computer-based techniques. The poor effectiveness of thermostable DNA polymerase, that lacks proof reading activity and inserts one incorrect nucleotide per 103–104 nucleotides in freshly synthesised strand, is the cause of error-prone PCR, which was initially reported by Goeddel and colleagues. Since errors can be enhanced by adding different quantities of dNTPs or by increasing the quantity of magnesium and manganese ions, libraries may be utilized for screening. Consequently, the genes will generate mutant copies that might result in different proteins [18]. Although error-prone programming is simple to use, it does not produce codons with regularly spaced amino acids, and the degeneracy of codons presents challenges since only one nucleotide is changed, making the total number of mutations insignificant. Additionally, polymerase mutations are biassed in favour of A and T transitions. Sequence saturation mutation (SeSaM), which segments genes using phosphothioate nucleotides that function as cleavage sites and produce fragments of varying lengths, is another method for tackling this issue. We call this strategy the random approach. After PCR amplification and deoxyinosine nucleotide incorporation at the 3' end, they elongate and produce a variety of mutant copies, mostly with distributed transversions, which are not obtained by PCR and are thus error-prone [19].

Focused mutagenesis:

Although a lot of libraries can be produced by random mutagenesis, not all of them will necessarily contain many functional proteins. Many of them could have deleterious mutations that inhibit the folding of proteins or render them inactive. Furthermore, it might be difficult to fully cover the majority of proteins. Focused mutagenesis is a substitute to random mutagenesis. It entails introducing mutations at certain protein locations, which may be catalytic sites or functional regions, producing a library of proteins with a variety of functions [20, 21]. A popular site-directed mutagenesis technique is inserting an oligonucleotide cassette containing certain codons into a vector. After transcription, this yields protein containing certain specified amino acids. A sequence of these eleven cassettes, each containing two codons, allows for the generation of mutations at any chosen location within the gene [22]. Site Saturated Mutagenesis is a further method that generates all twenty potential amino acids at a codon by substituting individual nucleotides [23]. This solves the codon degeneracy issue.

Recombination based mutagenesis:

Modifications in an organism's genome are entirely caused by recombination in the natural world. DNA shuffling is a useful method that uses overlapping regions that act as random primers in a PCR process to rebuild fragmented DNA fragments. It involves the genetic material moving in response to complementary DNA strands. [24] By using synthetic oligonucleotides as overlapping primers, this technique has been refined to provide a full mutant gene product. [25] Excision Technology and Nucleotide Exchange is another fragment-based technique that uses PCR to add a uridine nucleotide to the gene sequence. Purinic/apyrimidinic lyases and uracil glycosylase are then used to treat the gene sequence, resulting in fragments of varying lengths that are further amplified into full-length unique copies of the gene utilizing internal primers. [26]

Screening Methodologies:

Diverse proteins that are synthesised in vitro or in vivo are subjected to screening after mutagenesis. A group of useful proteins is obtained by screening, after which a targeted or desired protein with improved qualities is chosen. When studying proteins thought to be enzymatic that are produced in bacterial cultures or in vitro water-in-oil emulsion compartments, a surrogate substrate that produces a signal that matches fluorescent, colorimetric, or any other type of optical property as a result of enzymatic activity is capable of being introduced to the media or the oil emulsion [27]. Aside from that, expression-mediated protein screening may be accomplished with reporter genes like GFP. Alternatively, bacterial lysates can also be examined by X-ray crystallography, conventional NMR, or chromatography techniques. Yeast surface proteins, more precisely the desired epitopes, can be fused with a variety of library members for high throughput screening, which can be recognized by fluorescently tagged antibodies. The Fluorescence Activated Cell Sorter (FACS) may be used to separate cells exhibiting the epitope antibody complex based on fluorescence.

Selection: A Complex Process

Following screening, proteins that pass screening proceed through many selection processes to see whether they are viable candidates for selection; the best candidate is selected. Every library member gets evaluated and divided in a sophisticated way at this point. A protein library member's binding to an immobilised target can serve as the basis for selection. The connection among a gene and its associated protein must be preserved for proper and synchronous selection to occur [28]. In order to do this, approaches known as cell surface exhibition or phage visualisation are employed. These techniques entail the interaction of an immobilised target with an expressed library member that has been fused with either coat proteins [29] or cell surface proteins [30]. Phage display is currently used to both the discovery of novel therapeutic antibodies and the investigation of protein-protein interactions [31]. Enzymes have been

used for the bulk of binding selection experiments. According to a different technique, the survival of an organism is linked to the replication and function of many proteins, such as those that cause antibiotic resistance in organisms. The relationship between the expression of a gene conferring antibiotic resistance and the activities of different protein members has also been studied. There are disadvantages to in vivo systems, including transformation efficiency and host genetic mutation. In vitro techniques can be used to get around this [20]. Under strictly regulated conditions, an in vitro technique known as ribosomal display demonstrates the stable association of a ribosome with mRNA and produced protein in the absence of a stop codon, preserving the relationship between gene and protein [32]. Enzymes that employ DNA or RNA as substrates can be chosen using in vitro systems. In this method, efficient nucleases and polymerases with thermostability were successfully produced [20].

De novo enzyme engineering:

Enzymes are synthesised de novo, meaning they are not based on their related parent enzyme; [33] rather, they are created from scratch while taking into account their reaction or substrate mechanism. De novo synthesis may be carried out by the use of (i) large-scale protein library searches using mRNA display; (ii) reaction mechanism understanding; and (iv) in silicorational layout. mRNA display develops a covalent link with the protein it encodes, which promotes fast amplification of the target protein. This makes it much easier to locate de novo proteins from bigger libraries than using phage and cell surface display approaches. [34, 35]

APPLICATIONS OF PROTEIN ENGINEERING

Medical and Therapeutic Applications:

There are a plethora of medicinal possibilities for protein editing. In the past, protein engineering has produced second-generation recombinant proteins with notable qualities for use in clinical and medical settings. [36]

Below is a list of a few of its uses:

- The main focus of protein engineering research is on improving treatments to fight cancer. Pre-targeted immunotherapy is just one of the latent treatments for cancer that is advised, and it has been seen to minimize radiation damage. It was expected that the implementation of this pre-targeted immunotherapy, which involved protein engineering, would be a successful cancer treatment58. Protein engineering and recombinant DNA technological advancements make it easier to create new antibodies that have promising anti-cancer therapeutic applications. [36, 37]
- The phrase "modular protein engineering" has been used recently to describe novel cancer treatments. Treatment plans that use tailored nano conjugates to target cells selectively are becoming more and more crucial. Furthermore, protein engineering may be used to create intelligent and versatile drug carriers at the nano scale. Targets might be found and chosen using a combination of these approaches for protein-based medication delivery. [38]
- Some of the other significant medicinal uses of protein engineering are a result of its advancements. The protein cationization approach is one of them, helping to generate new treatments in the future. [39]
- Protein engineering also included tissue regeneration as well as polymer-based medication delivery systems as key objectives. [40]
- There has been much validity to the successful work over the past thirty years in identifying genetic abnormalities before they are diagnosed in people through fetal implantation. A 10% error rate in the rationale of over 300 genes was seen as a result of the whole genome of *Mycoplasma genetalium* being shown to be synchronizing with relevant protein sequences. [41, 42]
- A review of the creation of recombinant proteins for medicinal reasons was conducted in 1996. The second-generation therapeutic protein products having application-dependent features generated via mutation, deletion, or fusion was said to be the outcome of protein engineering. The 3rd generation of these proteins, which the patients would create after gene transfer, was referred to as "gene therapy" products made from protein. [43]
- The feasibility of "antibody engineering" has been enabled by the advancement of the technology for recombinant DNA. Antigenized antibodies and minimum recognition units were among the new characteristics that were included. In order to create antibodies with the required antigen binding capabilities, hybridoma technology has been shown to be significantly outperformed by combinational approaches such as bacteriophage display libraries. [44]

Smart response drug systems: Smart response drug systems are a promising field of drug research that has a lot to gain from improved protein engineering capabilities. Pharmaceutical systems with smart response ideally employ feedback mechanisms to cleverly adjust a therapeutic impact in response to biomarkers or other relevant inputs. A medication is released in a number of the current delayed release

techniques gradually and basically constantly. Conversely, intelligent drug delivery systems rely on outside inputs to control the amount of drug released in feedback-modulated release systems or to start the release of the drug in activation-modulated release systems [96]. Among these mechanisms is the Drug Buffer, an extra therapeutic component that actively keeps the serum free drug concentration within a safe and effective range when used with a therapy that has a restricted therapeutic window. [45] The use of human serum albumin (HSA) as a therapeutic carrier to extend the half-lives of protein and smaller-molecule medicines has advanced significantly in recent years. Either conjugation or linking fatty acids or other substances that have been demonstrated to bind to HSA can accomplish this. The FDA has authorized Abraxane®, an albumin-bound version of paclitaxel, for the treatment of certain metastatic prostate malignancies and lung cancers [46].

Protein Engineering of Therapeutic Enzymes: Due to their capacity to swiftly and precisely catalyse biochemical reactions in biological systems, enzymes are becoming more important in the pharmaceutical sector. Because enzyme-based therapies have such a profound impact on human health, they are increasingly becoming the subject of current study. [47]

There are several applications for enzymes as therapeutic agents. Some are given in Table 1. Despite their potential therapeutic benefits, their use is limited due to a number of drawbacks, such as low substrate affinity, variability in physiological settings, a tendency toward proteolytic cleavage, and increased catalytic activity, all of which are detrimental to diagnosis. Enzyme engineering provides a solution to all of these limitations by transforming an enzyme into a therapeutic target. [36, 48] In order to achieve desired functionality, protein engineering involves either creating new enzymes or altering the structure and/or sequence of existing enzymes. [49]

Table 1 A small number of proteins and associated engineering methods that have been modified to treat illnesses. [50]

Disease	Engineered Protein	Technology used	Role of the engineered proteins
Eye Diseases	Ciliary Neurotrophic Factor-Src homology 3 fusion protein	Mathematical modeling and protein fusion	Effective distribution
Cancer	E2 subunit of pyruvate dehydrogenase	Caged protein nanoparticle	Effective assimilation by dendritic cells
Ebola	Epitope-based peptide vaccine	Combination of molecular docking , epitope predictions, and MD simulation	Against the Ebola virus, designed epitopes demonstrated durable defensive response.
Inflammation	Tissue inhibitor of metalloproteinase-3 and Latency-associated peptide	Fusion protein technology	Particular suppression of the adamalysins' proteases and those of adamalysins featuring thrombospondin patterns
Foot-and-mouth disease	Multi-epitope recombinant proteins A6, A7 and A8	Gene fusion	Enhanced antigen-specificity
Osteoporosis	Tripeptides	Genetic programming (Artificial intelligence)	Inhibition of Cathepsin K
Plant based vaccines , Bacterial infection	Artificial protein OmpAVac	In silico approaches , rational design approach	Created as a potential protein vaccine to prevent infection with *E. coli* K1

Industrial applications:

Many different sectors, including the food, leather, cosmetic, pharmaceutical, paper, and chemical industries, use a variety of enzymes. The first examples of scientists using protein engineering to develop new enzymes for the biotechnological industries date back to the early 1990s. [51]

In the food processing process, the food business uses a range of enzymes, primarily proteases, lipases, and amylases. High temperatures, a broad pH range, and a variety of additional materials that might prevent or hinder enzyme activity are frequently required for these processes. Therefore, in order to solve these problems and further raise their output and activity, enzymes' selectivity, thermostability, and catalytic activity are strengthened by allowing the use of innovative protein engineering techniques. [1] Wheat gluten proteins present a significant application area for protein engineering in the food business. Apart from protein engineering, many expression platforms such as yeasts, E. coli, and cultivated insect cells have been employed to investigate their heterologous expression. [52] The food business uses a range of food-processing enzymes, including lipases and amylases, whose characteristics are enhanced using protein engineering and recombinant DNA technologies. [53]

Proteases:

Uses of Proteases-

- The food industry uses proteases for a number of applications, such as milk clotting, flavoring, and low-allergen infant formulas. They are also essential to the detergent industry's attempts to get rid of protein stains. [51]
- Bacterial alkaline proteases are a significant class of proteases in terms of their commercial value. Savinase, subtilisin Carlsberg, and subtilisin BPN are commercial products that are of special importance to the detergent industry. [53]

Protease production using protein engineering applications:

- Using protein engineering to improve proteases for industrial use—for example, to give them more stability at high temperatures or more activity at colder temperatures and alkaline pH—is difficult. In order to understand the role of proteases in virulence and to achieve overproduction, microbial protease genes have also been studied for protein engineering to enhance enzymatic capabilities. [54]
- Proteases can be improved by applying protein engineering techniques. For example, mesophilic subtilisin-like proteases can be cold adapted through laboratory evolution; [55] DNA shuffling is another technique for separating new proteases with enhanced characteristics from a starting base composed of 26 subtilisin proteases. [56]
- The catalytic efficacy, stability against oxidation, elevated temperatures, and changes in washing conditions were all enhanced by the use of protein engineering techniques.
- Novel alkaline proteases, including Purafect, Durazym, and Maxapem, were produced by random mutagenesis and/or site-directed mutagenesis, while novel subtilisin products with enhanced stability and selectivity were produced via directed evolution.
- Novel methodologies to identify novel microbial sources with improved alkaline protease activity have also been proposed, including the current "metagenomic" techniques to find natural and molecular diversities. [57]

Amylases:

Uses of Amylases-

- In the food sector, they are used to liquefy and saccharify starch as well as alter the quantity and suppleness of flour and bread during baking.
- The detergent industry uses amylases to remove starch stains. [51]

Applications of protein engineering in development of Amylases-

- It has been investigated how starch may be converted to bioethanol or useful components including fructose, wine, glucose, and trehalose. In order to liquefy and saccharify starch for such a conversion, microbial fermentation must occur in with the help of biocatalysts such amylases. Technologies such as protein engineering, recombinant enzymes, and enzyme immobilization have all been utilized to enhance amylases' highly sought-after commercial features, which include notable activity, high pH and high productivity , thermostability etc. [53]

Lipases:

Uses of Lipases-

- They are utilized in a wide range of food industry applications, including applications that include cheese flavor and dough conditioning and stability (as an in situ emulsifier).
- Because lipases are employed to remove lipid stains, they are additionally essential to the detergent business. [51]

Applications of protein engineering in development of Lipases-

- Since lipases are often employed in food industry applications, the food business must ensure that its lipases are toxicologically safe. This criterion is satisfied by commercially available lipase isoform combinations made from *Candida rugosa*. Purified and unique C. rugosa lipase isoforms may be

produced via protein engineering methods such as lid swapping, DNA rearranging, and computer modeling of lipase isoforms. [58]

Protein engineering in nano-biotechnology:

- Applications of protein engineering in nanobiotechnology are becoming more and more relevant. In moist surroundings and moderate physiological circumstances, biological macromolecules including proteins, lipids, and carbohydrates are used in the creation of biological tissues. The process is genetically controlled. Because of their involvement in physical performance, transport, tissue formation control, and biological activities, proteins in particular are essential components of biological systems. They are therefore appropriate parts for the controlled synthesis and construction of nanotechnological systems.
- The bacterial cell surface display as well as phage display technologies, which are combinatorial methods in biology employed in protein engineering, finds usage in nanobiotechnology to track the selective binding of polypeptide sequences to inorganic surfaces. [53]
- Through the use of Genetically Engineered Proteins (GEPIs), which are proteins that are engineered to mimic the self-arrangement of molecular systems, nanobiotechnology achieved even greater success.
- Following this, several particular peptides that are bonded to certain surfaces, such as gold and quartz, have been chosen and described. [59, 60] Additionally, the aim of enhancing peptide binding engineering and precisely assembling nanotechnology systems has led to the combination of computational and experimental methods in order to uncover better function-specific peptides that could be used in tissue engineering, therapeutics, and nanotechnologies that make use of inorganic, biological, and organic materials. [61]
- Protein-engineered peptides are used to create biocompatible nanomaterials and are employed as molecular motors and transducers in biosensors. A significant influence of bioinformatics analysis is also seen in the newly-emerging area of protein engineering. [62]
- Because amyloid fibrils serve as templates for the production of nanowires, they are another appealing application of protein engineering. [63]

Other emerging applications:

- Protein engineering techniques have produced new proteins known as affibody binding proteins, which are not derived from immunoglobulin (Ig). Due to their strong affinity, they may also be taken into consideration for bioseparation, viral targeting, tumor imaging, and diagnostics. [62, 63]
- In a decade, it has been seen that insertional protein engineering has become more important for the creation of new biosensors for analytical diagnostics. [8, 64]
- Several aspects of directed evolution have been seen to set it apart from natural evolution, such as the degree of selectivity exhibited by the mechanisms at hand and potential selection forces. As a result, the potential provided by methods that let enzymologists or protein engineers relate sequence to (structure and) activity in silico are firmly highlighted here as useful approaches for modeling and therefore investigating protein landscapes. Concurrently, this provides potential for protein enhancement not easily accessible to natural evolution on short timeframes, as recognized landscapes may be evaluated and reasoned about collectively. [65, 66]
- In the context of the biofuel business, protein engineering is used to generate cellulose enzymes, which increase catalytic activity and lower the cost of producing biofuels from lignocellulosic resources (such as biomass). [67]
- One method of protein engineering that creates proteins with a variety of functions is protein cysteine modification. [68, 69]

CONCLUSION

One use of recombinant DNA technology that has become a major biotechnological intervention and revolutionized the discovery and development of modern medications and diagnostics is protein engineering. Since protein sequences may be used to generate significant outcomes through computer algorithms and procedures, rational design—which necessitates previous knowledge—has gained importance. Directed evolution does offer a realistic possibility of generating proteins that would not be found in nature, but it is a drawn-out process that involves screening and selection. While traditional methods have always been helpful, the study of characteristics now encompasses a greater variety of functional aspects because to protein engineering. Proteases and amylases are two instances of altered enzyme classes with significant uses in the food, paper, detergent, and other industries. Engineered antibodies are one type of medicinal product that is offered. Proteomics-derived proteins have use in biosensors and diagnostics. Additionally, this business is beneficial to nanobiotechnology. Specifically, the progress made in the field of enzyme-based drugs offers a multitude of prospects for the creation of highly

customized and effective treatments. Whether the enzyme is the therapy itself, is required for the synthesis of the active drug, or serves as a tool for clinical biomarker detection, these organic molecules are a powerful and essentially infinite source for therapeutic uses in protein engineering alongside genetic diversity. In the last 20 years, methods to therapeutic enzyme engineering have generally advanced protein engineering. Currently, fundamental and biotechnological research uses readily accessible protein engineering approaches. Before protein engineering may reach its full potential, a few practical problems must be fixed.

REFERENCES

1. Mishra, S., Kumar, A., Tiwari, M., Singh, R.B., Mahdi, A.A., (2019). A review on conventional and modern techniques of protein engineering and their applications. Am. J. Biochem. Mol. Biol., 9: 17-28.
2. Fersht, A., Winter, G., (1992). Protein engineering. Trends Biochem Sci., 17, 292–295.
3. Protein Folding. (2011). Chemistry LibreTexts. Retrieved 19 May 2017, from http://chemwiki.ucdavis.edu /Core/Biological_Chemistr y/Proteins/Protein_Structure/Protein_Folding.
4. Dill, K.A., MacCallum, J.L., (2012). The protein-folding problem, 50 years on. Science., 338(6110): 1042-1046.
5. Van den Berg, B.A., Reinders, M.J.T., Van der Laan, J-M., Roubos, J.A., de Ridder, D., (2014) Protein redesign by learning from data. Protein Engineering, Design & Selection 27: 281-288.
6. Ali MA, Muzaffar A, Awan MF, Din S, Nasir IA, et al. (2014) Genetically modified foods: Engineered tomato with extra advantages. Adv. Life Sci 1: 139-152.
7. Ali MA, Rehman I, Iqbal A, Din S, Rao AQ, et al. (2014) Nanotechnology, a new frontier in Agriculture. Adv Life Sci 1: 129-138
8. Currin, A., Swainston, N., Day, P.J., Kell, D.B., (2015). Synthetic biology for the directed evolution of protein biocatalysts: Navigating sequence space intelligently. Chem. Soc. Rev., 44: 1172-1239.
9. Israr, M., Ilyas, M., Rahman, Z., (2014). Copy number variation in forensic science. Adv. Life Sci., 1: 71-72.
10. Zeymer, C., Hilvert, D., (2018). Directed evolution of protein catalysts. Annu. Rev. Biochem., 87: 131-157.
11. Bornscheuer, U., Pohl, M., (2001). Improved biocatalysts by directed evolution and rational protein design. National Center for Biotechnology Information. Retrieved 19 May 2017, from http://www.ncbi.nlm. nih.gov/pubmed/11282339
12. Arnold, F., (1993) Engineering proteins for nonnatural environments. The FASEB journal., 7(9): 744-749.
13. Antikainen, N.M., Martin, S.F., (2005). Altering protein specificity: techniques and applications. Bioorganic & medicinal chemistry., 13(8): 2701-2716.
14. Kontoravdi, K.M.P.aC., (2013) Synthetic Biology, Methods in Molecular Biology, (eds.).,. Springer Science+Business Media New York., 1073.
15. Krishnamurthy, V.V., Khamo, J.S., Cho, E., Schornak, C., Zhang, K., (2015). Polymerase chain reaction-based gene removal from plasmids. Data Brief, 4: 75-82.
16. Barnes HE, Liu G, Weston CQ, King P, Pham LK, et al. (2014). Selective microbial genomic DNA isolation using restriction endonucleases. PloS one., 9(10): e109061.
17. Zheng, L., Baumann, U., Reymond, J-L. (2004). An efficient one-step site-directed and site-saturation mutagenesis protocol. Nucleic Acids Research., 32(14): e115-e115.
18. Leung DW, Chen E, Goeddel DV. A method for random mutagenesis of a defined DNA segment using a modified polymerase chain reaction. Technique, (1989); 1(1): 11-15.
19. Wong TS, Tee KL, Hauer B, Schwaneberg U. Sequence saturation mutagenesis (SeSaM): a novel method for directed evolution. Nucleic Acids Research, (2004); 32(3): e26-e26.
20. Packer, M.S., Liu, D.R. (2005). Methods for the directed evolution of proteins. Nature Reviews Genetics., 16(7): 379-394.
21. Saif R, Khan E, Azhar A, Choudhary S, Hussain T, et al. (2016) Insight of Tp53 Mutations and their effect on Protein in Different Feline and Canine Neoplasms. Advancements in Life Sciences., 3(2): 42-50.
22. Kegler-Ebo, D.M., Docktor, C.M., DiMaio, D. (1994). Codon cassette mutagenesis: a general method to insert or replace individual codons by using universal mutagenic cassettes. Nucleic acids research., 22(9): 1593-1599.
23. Siloto, R.M., Weselake, R.J. (2012). Site saturation mutagenesis: Methods and applications in protein engineering. Biocatalysis and Agricultural Biotechnology., 1(3): 181- 189.
24. Lande ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001). Initial sequencing and analysis of the human genome. Nature, 409: 860-921.
25. Ness JE, Kim S, Gottman A, Pak A, Krebber A, et al. (2002). Synthetic shuffling expands functional protein diversity by allowing amino acids to recombine independently. Nature Biotechnol., 20: 1251-1255.
26. Muller, K.M., Stebel, S.C., Knall, S., Zipf, G., Bernauer, H.S., Arndt, K.M., (2005). Nucleotide exchange and excision technology (NExT) DNA shuffling: A robust method for DNA fragmentation and directed evolution. Nucl. Acids Res., 33: e117-e117.
27. Zhao, H., Giver, L., Shao, Z., Affholter, J.A., Arnold, F.H. (1998). Molecular evolution by staggered extension process (StEP) in vitro recombination. Nature Biotechnology., 16: 258-261.
28. Silwoski, G., Kothiwale, S.K., Meiler, J., Lowe Jr, E.W. (2014). Computational methods in drug discovery. Pharmacol Rev., 66: 334-395.
29. Mccafferty, J., Griffiths, A.D., Winter, G., Chiswell, D.J. (1990). Phage antibodies: filamentous phage displaying antibody variable domains. Nature., 348: 552-554.

30. Bessette, P.H., Rice, J.J., Daugherty, P.S. (2004). Rapid isolation of highaffinity protein binding peptides using bacterial display. Protein Engineering Design and Selection., 17: 731-739.
31. Liu, J.K.H., (2014). The history of monoclonal antibody development– Progress, remaining challenges and future innovations. Annals of Medicine and Surgery., 3: 113-116.
32. Hanes, J., Pluckthun, A. (1997). In vitro selection and evolution of functional proteins by using ribosome display. Proceedings of the National Academy of Sciences., 94: 4937-4942.
33. Seelig, B., Szostak, J.W., (2007). Selection and evolution of enzymes from a partially randomized non-catalytic scaffold. Nature., 448: 828-831.
34. Golynskiy, M.V., Seelig, B. (2010). De novo enzymes: From computational design to mRNA display. Trends Biotechnol., 28: 340-345.
35. Ali, M.A., Abbas, A. (2016). Analysis of reporter proteins GUS and DsRed driven under the control of CaMV35S promoter in syncytia induced by beet cyst nematode Heterodera schachtii in Arabidopsis roots. Adv. Life Sci., 3: 89-96.
36. Kurtzman, A.L., Govindarajan, S., Vahle, K., Jones, J.T., Heinrichs, V., Patten, P.A. (2001). Advances in directed protein evolution by recursive genetic recombination: Applications to therapeutic proteins. Curr. Opin. Biotechnol., 12: 361-370.
37. Lam, L., Liu, X.Y., Cao, Y. (2003). Pretargeted radioimmunotherapy, a potential cancer treatment. Drugs Future., Vol. 28. 10.1358/dof.2003.028.02.856929.
38. Vazquez, E., Ferrer-Miralles, N., Mangues, R., Corchero, J.L., Schwartz, S., Villaverde, A. (2009). Modular protein engineering in emerging cancer therapies. Current Pharmaceutical Design., Vol.15, No.8, pp. 893-916, ISSN: 1381-6128
39. Futami, J., Kitazoe, M., Murata, H., Yamada, H., (2007). Exploiting protein cationization techniques in future drug development. Exp. Opin. Drug Discovery., 2: 261-269.
40. Liu, S., Maheshwari, R., Kiick, K.L. (2009). Polymer-based therapeutics. Macromolecules., 42: 3-13.
41. Mishra, S., Maheshwari, S.K. (2008). Development of Protein Nanotechnology: Applications in Disease Diagnosis at Proteomics Level. Pointer Publishers, Jaipur, India, pp: 70-76.
42. Davis, R.H. (2007). Beadle's progeny: Innocence rewarded, innocence lost. J. Biosci., 32: 197-205.
43. Buckel, P. (1996). Recombinant proteins for therapy. Trends in Pharmacological Sciences, Vol.17, No.12, pp.450-456, ISSN: 0165-6147.
44. Sandhu, J.S. (1992). Protein engineering of antibodies. Critical Reviews in Biotechnology., Vol.12, No.5-6, pp.437-462, ISSN: 0738-8551.
45. De Wolf, F.A., Brett, G.M. (2000). Ligand-binding proteins: Their potential for application in systems for controlled delivery and uptake of ligands. Pharmacol Rev., 52(2):207–236. [PubMed: 10835100]
46. Kratz, F. A clinical update of using albumin as a drug vehicle — A commentary. Journal of Controlled Release. (0)
47. Wohlgemuth, R. (2007). Modular and scalable biocatalytic tools for practical safety, health and environmental improvements in the production of speciality chemicals. Biocatalysis and Biotransformation., 25(2-4): p. 178-185.
48. Vasserot AP, et al. (2003). Optimization of protein therapeutics by directed evolution. Drug discovery today., 8(3): p. 118-126.
49. Dhanjal, JK, et al. (2019). Computational Protein Engineering Approaches for Effective Design of New Molecules.
50. Mandeep, Sinha, R., Shukla, P. (2019). Protein Engineering for Improved Health: Technological Perspectives. Curr Protein Pept Sci., 20(9):856-860. doi: 10.2174/1389203720091909170953O7. PMID: 31566124.
51. Kirk, O., Borchert, T.V., Fuglsang, C.C. (2002). Industrial enzyme applications. Curr. Opin. Biotechnol., 13: 345-351.
52. Tamas, L., Shewry, P.R. (2006). Heterologous expression and protein engineering of wheat gluten proteins. Journal of Cereal Science., Vol.43, No.3, (May 2006), pp.259-274, ISSN: 0733-5210.
53. Turanli-Yildiz, Burcu, et al. (2012). 'Protein Engineering Methods and Applications'. Protein Engineering, InTech. 24 Feb. 2012. Crossref, doi:10.5772/27306.
54. Rao, M.B., Tanksale, A.M., Ghatge, M.S., Deshpande, W. (1998). Molecular and biotechnological aspects of microbial proteases. Microbiology and Molecular Biology Reviews., Vol.62, No.3, pp.597-635, ISSN: 1092-2172.
55. Wintrode, P.L., Miyazaki, K., Arnold, F.H. (2000). Cold adaptation of a mesophilic subtilisin-like protease by laboratory evolution. Journal of Biological Chemistry., Vol.275, No.41, pp.31635-31640, ISSN: 0021-9258.
56. Ness, J.E., Welch, M., Giver, L., Bueno, M., Cherry, J.R., Borchert, T.V., Stemmer, W.P.C., Minshull. J. (1999). DNA shuffling of subgenomic sequences of subtilisin. Nature Biotechnology., Vol.17, pp.893-896, ISSN: 1087-0156.
57. Gupta, R., Beg, Q.K., Lorenz, P. (2002). Bacterial alkaline proteases: molecular approaches and industrial applications. Applied Microbioology and Biotechnology., Vol.59, No.1, pp.15-32, ISSN: 0175-7598.
58. Akoh, C.C., Lee, G.C., Shaw, J.F. (2004). Protein engineering and applications of Candida rugosa lipase isoforms. Lipids., Vol.39, No.6, pp.513-526, ISSN: 0024-4201.
59. Seker, E., Reed, M., Begley, M. (2009). Nanoporous gold: Fabrication, characterization and applications. Materials., 2: 2188-2215.
60. Oren, M., Rotter, V., (2010). Mutant p53 gain-of-function in cancer. Cold Spring Harbor Perspect. Biol., Vol. 2. 10.1101/cshperspect.a001107.
61. Tamerler, C., Khatayevich, D., Gungormus, M., Kacar, T., Oren, E.E., Hnilova, M., Sarikaya, M. (2010). Molecular biomimetics: GEPI based biological routes to technology. Peptide Sci.: Orig. Res. Biomol., 94: 78-94.
62. Hamada, D., Yanagihara, I., Tsumoto, T. (2004). Engineering amyloidogenicity towards the development of nanofibrillar materials. Trends Biotechnol., 22: 93-97.

63. Banta, S., Megeed, Z., Casali, M., Rege, K., Yarmush, M.L. (2007). Engineering protein and peptide building blocks for nanotechnology. J. Nanosci. Nanotechnol., 7: 387-401.
64. Ferraz RM, Vera A, Aris A, Villaverde A, 2006. Insertional protein engineering for analytical molecular sensing. Microb. Cell Fact., Vol. 5, No. 1. 10.1186/1475-2859-5-15.
65. Klug, A. (2010). The discovery of zinc fingers and their development for practical applications in gene regulation and genome manipulation. Quart. Rev. Biophys., 43: 1-21.
66. Gersbach, C.A., Gaj, T., Barbas, C.F. III. (2014). Synthetic zinc finger proteins: The advent of targeted gene regulation and genome modification technologies. Accounts Chem. Res., 47: 2309-2318.
67. Wen, F., Nair, N.U., Zhao, H. (2009). Protein engineering in designing tailored enzymes and microorganisms for biofuels production. Curr. Opin. Biotechnol., 20: 412-419.
68. Dozier, J., Distefano, M. (2015). Site-specific PEGylation of therapeutic proteins. Int. J. Mol. Sci., 16: 25831-25864.
69. Nagahara, N., Matsumura, T., Okamoto, R., Kajihara, Y. (2009). Protein cysteine modifications: (2) Reactivity specificity and topics of medicinal chemistry and protein engineering. Curr. Med. Chem., 16: 4490-4501.

CITATION OF THIS ARTICLE

Manisha S, Saumya G, Shaffi T. Protein Engineering: A Holistic Approach To Techniques And Its Uses. Bull. Env.Pharmacol. Life Sci., Vol 12 [7] June 2024: 39-48